Back to News

Aragen expands collaboration with Blueprint MedicinesTo provide discovery services to support Blueprint Medicines’ emerging pipeline of targeted protein degraders

Hyderabad: Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), headquartered in Hyderabad, India, announced the expansion of its collaboration with Blueprint Medicines Corporation (Blueprint Medicines) (Cambridge MA, USA) to provide Integrated Drug Discovery solutions supporting Blueprint Medicines’ emerging pipeline of targeted protein degraders.

“We look forward to continuing to work with Blueprint Medicines researchers to advance its pipeline of therapeutic candidates,” said Manni Kantipudi, CEO of Aragen. “At Aragen, our team believes that ‘in every molecule is the possibility for better health’. By treating every project with urgency and focus, we look to discover and develop medicines for our collaborators that make a positive impact on patients.”

Dr. Simon Haydar, SVP & BU head of Integrated Drug Discovery at Aragen, added: “On behalf of everyone at Aragen, I would like to thank Blueprint Medicines for their trust and confidence in us and their decision to expand on our collaboration. Over the past year, we have worked diligently at building a world-class scientific team, working and collaborating with Blueprint Medicines to advance transformative therapies that we believe will make a difference in patients’ lives.”

Dr. Percy Carter, CSO of Blueprint Medicines, added, “Blueprint’s focus on precision medicine has delivered two transformative therapies for patients within its first decade in operation. Our partnership with Aragen is valuable as we advance our research efforts, and we are happy to extend the partnership.”

About Aragen: Aragen Life Sciences is a leading R&D and manufacturing solutions provider to the global life sciences industries. Aragen offers a range of solutions across the drug development continuum to advance small and large molecule programs. With more than 20 years of experience, the Company operates through a global network of six sites with a team of 3800+ employees and 450+ PhDs. Its expertise and experience have enabled over 450 customers (including 7 of the top 10 pharma companies globally) in advancing their research programs from early discovery through development and commercialization. Aragen’s innovative mindset, infrastructure, flexible business models, a clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and animal health industries globally. Visit www.aragen.com for more details.

Media Contact:
Aragen Life Sciences: Sandeep Nair, +91 8179955673, Sandeep.nair@aragen.com